The CAR-T Quality Blind Spot: Why $500K Therapies Still Fail Half the Time

CAR-T therapy costs $500K per dose, yet fewer than 50% of patients achieve durable responses. 33% of lymphoma patients never reach infusion due to manufacturing failure. A 36-marker spectral flow cytometry panel reveals what standard 4-6 marker QC completely misses — Day 5 stem-like cells vs Day 10 exhausted cells look identical under current testing. With next-day manufacturing racing ahead while QC testing still takes 14-42 days, AI-driven quality prediction isn't optional. It's the only path